Tam M N, Nam N H, Jin G Z, Song G Y, Ahn B Z
College of Pharmacy, Chungnam National University, Taejon, Korea.
Arch Pharm (Weinheim). 2000 Jun;333(6):189-94. doi: 10.1002/1521-4184(20006)333:6<189::aid-ardp189>3.0.co;2-t.
2-(1-Hydroxyiminoalkyl)-1,4-dimethoxy-9,10-anthraquinones were demethylated to produce 2-(1-hydroxyiminoalkyl)-1,4-dihydroxy-9,10-anthraquinones (1,4-dihydroxy-9,10-anthraquinone, DHAQ), oxime hydroxyl groups were in turn acylated to give the corresponding 2-(1-acyloxyiminoalkyl)-DHAQ derivatives. The anti-proliferative activity of 2-(1-hydroxyiminoalkyl)-DHAQ derivatives was found to be dependent on the size of an alkyl chain. Thus, DHAQ analogues with alkyl chains longer than heptyl had negligible anti-proliferative activity, whilst those compounds possessing shorter chains demonstrated moderate anti-proliferative activity (ED50, 2.73-19.21 microM). However, the antitumor activity as expressed by T/C values did not correlate with the anti-proliferative activity; 2-(1-hydroxyiminononyl)-DHAQ with an ED50 value of more than 20 microM exhibited potent antitumor activity (T/C, 166%). Only four of the 2-(1-hydroxyiminoalkyl)-DHAQ analogues showed good antitumor activity (T/C, > 150%); 2-(1-hydroxyiminobutyl)-DHAQ (T/C, 163%), 2-(1-hydroxyiminopentyl)-DHAQ (T/C, 180%) and 2-(1-hydroxyiminononyl)-DHAQ (T/C, 166%). Acylation of the hydroxyl group of these oximes enhanced the anti-proliferative activity and antitumor effects; 2-(1-propanoyloxyiminopropyl)-DHAQ (ED50, 4.41 microM; T/C, 221%) vs. 2-(1-hydroxyiminopropyl)-DHAQ (ED50, 14.64 microM; T/C, 100%) and 2-(1-propanoyloxyiminobutyl)-DHAQ (ED50, 2.65 microM; T/C, 202%) vs. 2-(1-hydroxyiminobutyl)-DHAQ (ED50, 16.43 microM; T/C, 163%).
2-(1-羟基亚氨基烷基)-1,4-二甲氧基-9,10-蒽醌发生去甲基化反应生成2-(1-羟基亚氨基烷基)-1,4-二羟基-9,10-蒽醌(1,4-二羟基-9,10-蒽醌,DHAQ),肟羟基依次被酰化得到相应的2-(1-酰氧基亚氨基烷基)-DHAQ衍生物。发现2-(1-羟基亚氨基烷基)-DHAQ衍生物的抗增殖活性取决于烷基链的长度。因此,烷基链长于庚基的DHAQ类似物的抗增殖活性可忽略不计,而那些具有较短链的化合物表现出中等抗增殖活性(半数有效剂量,2.73 - 19.21微摩尔)。然而,以T/C值表示的抗肿瘤活性与抗增殖活性不相关;半数有效剂量值超过20微摩尔的2-(1-羟基亚氨基壬基)-DHAQ表现出强效抗肿瘤活性(T/C,166%)。2-(1-羟基亚氨基烷基)-DHAQ类似物中只有四种表现出良好的抗肿瘤活性(T/C,> 150%);2-(1-羟基亚氨基丁基)-DHAQ(T/C,163%)、2-(1-羟基亚氨基戊基)-DHAQ(T/C,180%)和2-(1-羟基亚氨基壬基)-DHAQ(T/C,166%)。这些肟的羟基酰化增强了抗增殖活性和抗肿瘤作用;2-(1-丙酰氧基亚氨基丙基)-DHAQ(半数有效剂量,4.41微摩尔;T/C,221%)对比2-(1-羟基亚氨基丙基)-DHAQ(半数有效剂量,14.64微摩尔;T/C,100%)以及2-(1-丙酰氧基亚氨基丁基)-DHAQ(半数有效剂量,2.65微摩尔;T/C,202%)对比2-(1-羟基亚氨基丁基)-DHAQ(半数有效剂量,16.43微摩尔;T/C,163%)。